Safeguard Scientifics, Inc. (SFES) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Safeguard Scientifics, Inc. (SFES) trades at $0.3671. Safeguard Scientifics, Inc. is a private equity and venture capital firm that formerly specialized in providing expansion and growth financing to technology, financial services, and healthcare companies. Market cap: $6.14M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SFES: SFES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SFES against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SFES.
How is this calculated? →Safeguard Scientifics, Inc. (SFES) Financial Services Profile
Safeguard Scientifics, Inc., based in Radnor, PA, is a private equity and venture capital firm focused on growth and expansion funding within the technology, financial services, and healthcare sectors. While historically active in early to growth-stage investments, the company is no longer making new investments as of 2026.
What Is the Investment Thesis for SFES?
Safeguard Scientifics, Inc. presents a complex investment case given its current state of no longer making new investments. With a market capitalization of $6.14M and a negative ROE of -36.0%, the company's financial performance raises concerns. The high debt-to-equity ratio of 6.25 indicates significant leverage. The company's beta of 0.28 suggests low volatility relative to the market. Investors should closely examine the company's existing portfolio and asset liquidation strategy. The absence of a dividend yield further reduces the attractiveness for income-seeking investors. Any potential value would likely stem from the strategic management of existing assets and the realization of value from its historical investments.
Based on FMP financials and quantitative analysis
SFES Key Highlights
Market capitalization of $6.14M indicates a small-cap company.
- Negative ROE of -36.0% reflects poor profitability and inefficient use of equity.
- Debt-to-equity ratio of 6.25 suggests high financial leverage.
- Free cash flow of $-0.00B indicates the company is not generating positive cash flow from operations.
- Beta of 0.28 suggests the stock is significantly less volatile than the market.
Who Are SFES's Competitors?
SFES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AINV Apollo Investment Corporation | $13.65 | +0.59% | $893M | 49 |
| BXSL Blackstone Secured Lending Fund | $24.59 | +0.10% | $5.72B | 56 |
| TPVG TriplePoint Venture Growth BDC Corp. | $5.38 | -2.00% | $218M | 41 |
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
| ALISR Calisa Acquisition Corp Right | $0.64 | +0.00% | 79 | |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SFES's Key Strengths?
Historical expertise in technology, financial services, and healthcare investing.
- Established network of industry contacts.
- Experience in providing value-added support to portfolio companies.
- Legacy of successful exits and value creation.
What Are SFES's Weaknesses?
No longer making new investments, limiting growth potential.
- Negative ROE indicates poor profitability.
- High debt-to-equity ratio increases financial risk.
- Small market capitalization limits access to capital.
What Could Drive SFES Stock Higher?
Potential sale of remaining portfolio companies.
- Cost reduction initiatives to improve profitability.
- Active management of existing assets to maximize returns.
What Are the Key Risks for SFES?
Financial-distress signal — its Altman Z-Score of -27.02 sits in the distress zone (elevated bankruptcy risk).
- Economic downturn could negatively impact the value of portfolio companies.
- Limited liquidity in the OTC market could make it difficult to trade shares.
- Negative ROE indicates poor profitability and inefficient use of equity.
- High debt-to-equity ratio increases financial risk.
What Are the Growth Opportunities for SFES?
- Monetization of Existing Portfolio Companies: Safeguard Scientifics can focus on maximizing the value of its current portfolio companies through strategic sales or IPOs. The market for strategic acquisitions remains robust, particularly for companies with innovative technologies or strong market positions in high-growth sectors. Successful exits could provide significant returns and enhance shareholder value. The timeline for these exits depends on market conditions and the performance of the individual portfolio companies.
- Operational Efficiency Improvements: Streamlining operations and reducing overhead costs can improve profitability and free up capital. By implementing cost-cutting measures and optimizing resource allocation, Safeguard Scientifics can enhance its financial performance and increase its attractiveness to potential acquirers or strategic partners. This is an ongoing effort with potential for immediate impact on the company's bottom line.
- Strategic Partnerships and Alliances: Collaborating with other financial institutions or private equity firms can provide access to new markets, technologies, and investment opportunities. Strategic partnerships can also help to diversify risk and enhance the firm's competitive position. The timeline for forming strategic partnerships depends on identifying suitable partners and negotiating mutually beneficial agreements.
- Leveraging Intellectual Property: Safeguard Scientifics can explore opportunities to license or commercialize its intellectual property assets. This can generate additional revenue streams and enhance the value of its portfolio companies. The market for intellectual property licensing is growing, driven by increasing demand for innovative technologies and solutions. The timeline for commercializing intellectual property depends on the specific assets and market conditions.
- Restructuring and Recapitalization: Exploring options for restructuring its balance sheet and recapitalizing the company can improve its financial flexibility and reduce its debt burden. This may involve issuing new equity, refinancing existing debt, or selling non-core assets. A successful restructuring can enhance the company's long-term sustainability and create value for shareholders. The timeline for restructuring depends on market conditions and the company's financial situation.
What Threats Does SFES Face?
- Economic downturn could negatively impact the value of portfolio companies.
- Increased competition in the private equity and venture capital industry.
- Regulatory changes could impact investment strategies.
- Inability to successfully exit portfolio companies could lead to losses.
What Are SFES's Competitive Advantages?
- Historical expertise in identifying and nurturing high-growth companies.
- Established network of industry contacts and strategic partners.
- Proprietary knowledge and insights into emerging trends in technology, financial services, and healthcare.
- Reputation for providing value-added support to portfolio companies.
What Does SFES Do?
Safeguard Scientifics, Inc., established in 1953 as Lancaster Corporation and rebranded in 1981, transitioned into a private equity and venture capital firm. Headquartered in Radnor, Pennsylvania, with an additional office in Weston, Massachusetts, the firm historically focused on providing expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, and early-stage financings. Safeguard Scientifics primarily targeted companies in the technology, financial services, and healthcare sectors, initially investing in Series A-C rounds and opportunistically in seed rounds. Within technology, their focus included software as a service, adtech, digital media, Internet of Everything, enhanced security, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, fintech, cloud, mobile, social, big data, and in-memory computing. In healthcare, they targeted molecular and point-of-care diagnostics, medical devices, regenerative medicine, digital health, specialty pharmaceuticals, and selected healthcare services. Geographically, Safeguard Scientifics invested throughout the United States, with a concentration in the Mid-Atlantic region and Southeastern Canada. Typical investments ranged from $5 million to $25 million for growth equity and $5 million to $10 million for early-stage financing. The firm sought to be the largest shareholder, aiming for 20% to 50% ownership, and preferred companies with proprietary technology and intellectual property, often taking a board seat. As of 2026, Safeguard Scientifics, Inc. is no longer making new investments.
What Products and Services Does SFES Offer?
- Historically invested in technology, financial services, and healthcare companies.
- Provided expansion and growth financing to portfolio companies.
- Focused on Series A-C rounds and opportunistic seed rounds.
- Targeted companies with proprietary technology and intellectual property.
- Took board seats in portfolio companies to guide strategy.
- Sought ownership stakes between 20% and 50% in portfolio companies.
- No longer making new investments as of 2026.
How Does SFES Make Money?
- Historically generated returns through capital appreciation of portfolio companies.
- Realized gains through strategic sales, IPOs, or recapitalizations of portfolio companies.
- No longer generating revenue through new investments.
- Currently focused on managing existing assets and liquidating portfolio holdings.
What Industry Does SFES Operate In?
Safeguard Scientifics operates within the asset management industry, a sector characterized by intense competition and evolving investment strategies. The industry is influenced by macroeconomic trends, interest rate fluctuations, and technological advancements. Firms compete on investment performance, fees, and client service. Given Safeguard Scientifics' current position of no longer making new investments, its competitive focus has shifted to managing existing assets and maximizing returns from its legacy portfolio. The overall asset management industry continues to grow, driven by increasing wealth and demand for sophisticated investment solutions.
Who Are SFES's Key Customers?
- Early-stage and growth-stage companies in technology, financial services, and healthcare seeking capital.
- Entrepreneurs and management teams looking for strategic investors.
- Limited partners in Safeguard Scientifics' funds.
Insider Activity
The most recent 6 insider filings for Safeguard Scientifics, Inc. break down as 4 sales and 2 purchases. On net that is roughly 5.7M shares acquired (about $128K) — insiders putting money in tends to read as conviction.
SFES Valuation & Market Position
With a $6.14M market cap, Safeguard Scientifics, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Safeguard Scientifics, Inc. stands at 131.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 67.9%, showing how much profit it generates from its asset base. SFES trades at a trailing price-to-earnings ratio of 0.30, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 40.00 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Safeguard Scientifics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -27.02 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Safeguard Scientifics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-3.52.
Company Profile
Safeguard Scientifics, Inc. operates in the Asset Management industry within the Financial Services sector. It is headquartered in Radnor, US. The company is led by CEO Mark R. Dow. SFES has traded publicly since 1980.
SFES Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future direction, indicating that those closest to the business see potential upside.
- Community sentiment has shifted positively, with discussions highlighting innovative projects and strategic partnerships that could drive growth.
- Analysts are noting an uptick in interest in the sectors Safeguard operates in, particularly in tech and healthcare, which are poised for expansion.
- The company's focus on digital transformation aligns with market trends, attracting attention from investors looking for forward-thinking firms.
Bear Case
- Despite recent insider buying, some analysts express caution, citing ongoing challenges in the competitive landscape that could hinder growth.
- Community sentiment shows mixed feelings, with some investors concerned about the sustainability of recent gains and the potential for volatility.
- There are worries about the company's ability to execute its strategic initiatives effectively, especially in a rapidly changing market environment.
- Market perception remains cautious, with discussions highlighting past underperformance and skepticism about the company's turnaround strategy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SFES Latest News
No recent news available for SFES.
SFES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SFES.
Price Targets
Wall Street price target analysis for SFES.
SFES MoonshotScore
What does this score mean?
The MoonshotScore rates SFES 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
SFES OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Safeguard Scientifics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available and may be subject to greater price volatility and lower liquidity compared to exchange-listed stocks on NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for less stringent regulatory oversight and reduced transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads increase transaction costs.
- Potential for price manipulation and fraud is higher on the OTC market.
- Reduced regulatory oversight compared to exchange-listed stocks.
- Going concern risk due to the company no longer making new investments.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive position.
- Analyze the company's capital structure and debt obligations.
- Review the company's legal and regulatory filings.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 1953.
- Previously traded on a major exchange before moving to OTC.
- Headquartered in Radnor, Pennsylvania, with an additional office in Weston, Massachusetts.
- Focus on technology, financial services, and healthcare sectors.
Safeguard Scientifics, Inc. Financial Services Stock: Key Questions Answered
What does Safeguard Scientifics, Inc. do?
Safeguard Scientifics, Inc. is a private equity and venture capital firm that historically invested in early-stage and growth-stage companies within the technology, financial services, and healthcare sectors. The firm provided expansion financing, growth capital, and management buyout support.
What do analysts say about SFES stock?
As of 2026, there is limited analyst coverage on Safeguard Scientifics, Inc. due to its small market capitalization and OTC listing. Key valuation metrics such as price-to-earnings ratio and price-to-book ratio are less relevant given the company's current state of no longer making new investments and its negative ROE.
What are the main risks for SFES?
The main risks for Safeguard Scientifics, Inc. include the potential for an economic downturn to negatively impact the value of its portfolio companies, the limited liquidity in the OTC market, which could make it difficult to trade shares, and the company's negative ROE, which indicates poor profitability. Additionally, the company's high debt-to-equity ratio increases financial risk.
How does Safeguard Scientifics, Inc. generate revenue?
Historically, Safeguard Scientifics, Inc. generated revenue through capital appreciation and successful exits of its portfolio companies. This involved selling its stakes in these companies through strategic acquisitions, initial public offerings (IPOs), or recapitalizations. Currently, with the company no longer making new investments, revenue generation is limited to managing existing assets and potentially liquidating portfolio holdings. The success of these activities directly impacts the company's financial performance and shareholder value.
What is Safeguard Scientifics, Inc.'s credit quality and risk management approach?
Given that Safeguard Scientifics, Inc. is a private equity and venture capital firm, traditional credit quality metrics are not directly applicable. However, the company's risk management approach historically involved thorough due diligence on potential investments, diversification across sectors and geographies, and active monitoring of portfolio company performance.
What are the key factors to evaluate for SFES?
Evaluate SFES on fundamentals, analyst consensus, and risk factors. Safeguard Scientifics, Inc. presents a complex investment case given its current state of no longer making new investments. Not financial advice.
How frequently does SFES data refresh on this page?
SFES's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SFES's recent stock price performance?
Safeguard Scientifics, Inc. (SFES) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Historical expertise in technology, financial services, and healthcare investing. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending for SFES.